From June 2026, USP <901> updates require asbestos testing in talc used across solid-dose manufacturing. Asbestos contamination in pharmaceutical-grade talc is the specific trigger for this change, and the consequences of non-compliance are real. For quality teams already managing tight production schedules and complex compliance obligations, resolving this requirement through a single, reliable laboratory partner is the clearest path forward.

SGS provides GMP-validated X-ray Powder Diffraction (XRPD) and polarised light microscopy (PLM) testing under one roof, giving manufacturers a single, defensible answer to the USP <901> requirement. If your talc is not tested, your batch release is at risk. Rather than coordinating between separate service providers, clients receive integrated results from one GMP-compliant laboratory, with validated methods aligned to USP <941> and European Pharmacopoeia standards, meaning cleaner documentation, faster decisions, and data your regulatory team can stand behind.

The same XRPD capability supports solid-state characterisation across the full product lifecycle — from polymorph screening and API development through to routine batch release and raw material identity testing. For manufacturers managing multiple programmes simultaneously, consolidating that analytical workload with a single qualified partner reduces coordination overhead and keeps timelines predictable.

SGS is the world’s leading testing, inspection and certification company. In pharmaceutical solid-state analysis, that means validated methods, experienced scientific teams, and quality standards built for the expectations of regulators across every major market. Whether working to USP, EP, or both, manufacturers gain a dependable analytical partner at the point where confidence in your data matters most.

Learn more about X-Ray Powder Diffraction (XRPD) services from SGS Ireland.